What is the 13F Pro Quality Score for VCYT?

13F Pro ranks VERACYTE, INC. (VCYT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VCYT's current score at https://13fpro.ai/research/VCYT (free sign-up required for the full ranking).

Which hedge funds own the most VCYT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VCYT include BlackRock,, FMR, Artisan Partners Limited Partnership. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VCYT as soon as new 13F filings post.

Where does 13F Pro source VCYT data?

All VERACYTE, INC. fundamentals and ownership data come directly from SEC EDGAR. VERACYTE, INC. files with the SEC under CIK 1384101. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VCYT in?

VERACYTE, INC. (VCYT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VCYT research updated on 13F Pro?

VCYT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VERACYTE, INC.(VCYT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1384101 VCYT stock profile & AI dashboard →

13F Pro Quality Score

59.5/100

Rank #919 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

38.5/100

Profitability

77.7/100

Balance Sheet

63.2/100

Earnings Quality

98.7/100

Free Cash Flow

79.4/100

Institutional Flow

67.6/100

Revenue Scale

37.3/100

Dilution Risk

19.0/100

VCYT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VERACYTE, INC. (VCYT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCYT at 59.5/100 on a 32-signal composite quality model, placing it at rank #919 of 2,879 stocks — the top half of the AI-ranked universe. VCYT scores in the top quartile across earnings quality (98.7), free cash flow (79.4), profitability (77.7). Areas of concern include revenue scale (37.3) and revenue growth (38.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), VERACYTE, INC. reports quarterly revenue of $139.1M, net income of $28.7M, free cash flow of $32.3M. Top institutional holders of VCYT by reported 13-F value include BlackRock,, FMR, Artisan Partners Limited Partnership, based on the most recent SEC filings. VCYT trades on the Nasdaq exchange and files with the SEC under CIK 1384101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCYT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERACYTE, INC. directly from SEC EDGAR. VERACYTE, INC.'s 13F Pro composite quality score has ranged between 8 and 76 since 2021, currently 59.5 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about VERACYTE, INC.

Quirks, history, and lore behind VCYT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. genomic diagnostics company · listed on Nasdaq · headquartered in South San Francisco, California · focused on cancer detection.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a business model built on test volume growth rather than near-term profitability.
3
The History
Founded in the early 2000s, the company grew by acquiring complementary diagnostics businesses and expanding beyond its original thyroid cancer testing niche.
4
The Secret
Its tests use gene expression profiling to tell surgeons whether a suspicious nodule is malignant — potentially sparing patients from unnecessary surgery.
5
The Lore
The company has pushed aggressively into urologic and breast cancers, aiming to become a one-stop genomic shop for oncologists who are tired of playing diagnostic guesswork.
6
The Giveaway
Its flagship Afirma test is the go-to molecular tool for thyroid nodule evaluation, and its ticker is just four letters away from sounding like something you'd find in a chemistry textbook.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$139.1M

Net Income

Q1 2026

$28.7M

Free Cash Flow

Q1 2026

$32.3M

ROIC

Q1 2026

1.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+16.0% YoY

$517.1MFY 2025

FY22 $296.5MFY23 $361.1MFY24 $445.8MFY25 $517.1M

Net Income

+175.1% YoY

$66.4MFY 2025

FY22 $-36.6MFY23 $-74.4MFY24 $24.1MFY25 $66.4M

Operating Income

+257.9% YoY

$57.8MFY 2025

FY22 $-41.1MFY23 $-85.8MFY24 $16.1MFY25 $57.8M

EPS (Diluted)

+164.5% YoY

$0.82FY 2025

FY22 $-0.51FY23 $-1.02FY24 $0.31FY25 $0.82

Total Assets

+8.2% YoY

$1.41BFY 2025

FY22 $1.16BFY23 $1.11BFY24 $1.30BFY25 $1.41B

Total Debt

—FY 2025

FY22 $0.00FY23 —FY24 —FY25 —

Op. Cash Flow

+81.5% YoY

$136.3MFY 2025

FY22 $7.5MFY23 $44.2MFY24 $75.1MFY25 $136.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$517.1M +16.0%	$445.8M +23.5%	$361.1M +21.8%	$296.5M +35.1%	$219.5M +82.4%	$120.4M
Net Income	$66.4M +175.1%	$24.1M +132.4%	$-74.4M -103.5%	$-36.6M +51.6%	$-75.6M -499.8%	$-12.6M
Operating Income	$57.8M +257.9%	$16.1M +118.8%	$-85.8M -108.8%	$-41.1M +49.8%	$-81.9M -441.4%	$-15.1M
EPS (Diluted)	$0.82 +164.5%	$0.31 +130.4%	$-1.02 -100.0%	$-0.51 +54.1%	$-1.11 -311.1%	$-0.27
Total Assets	$1.41B +8.2%	$1.30B +16.6%	$1.11B -3.6%	$1.16B -2.6%	$1.19B +331.6%	$275.2M
Total Debt	—	—	—	$0.00 -100.0%	$1.1M +62.4%	$694.0K
Operating Cash Flow	$136.3M +81.5%	$75.1M +69.8%	$44.2M +486.9%	$7.5M +123.8%	$-31.6M -878.4%	$-3.2M

AI Insight: VCYT Financial Trends

VCYT delivered strong revenue acceleration and margin expansion with Q4 2025 operating income surging to $37M from prior year's $4M.

• Revenue accelerated from $114M in Q1 2025 to $141M in Q4 2025, marking 24% growth over four quarters.

• Operating income expanded dramatically from $3M in Q1 2025 to $37M in Q4 2025, showing strong operational leverage.

• Operating cash flow strengthened from $5M in Q1 2025 to $53M in Q4 2025 before moderating to $35M.

⚠ Revenue declined sequentially from $141M in Q4 2025 to $139M in Q1 2026, breaking four-quarter growth streak.

⚠ Operating cash flow dropped from $53M peak in Q4 2025 to $35M in Q1 2026, signaling potential working capital pressures.

AI Insight: VCYT Ratio Trends

Operating margin surged from -4.0% in Q2 2025 to 26.5% in Q4 2025, driving ROIC to 11.4% before moderating to 6.7% in Q1 2026.

• Operating margin expanded dramatically from -4.0% in Q2 2025 to 26.5% in Q4 2025, then moderated to 16.3% in Q1 2026.

• ROIC jumped from -1.7% in Q2 2025 to 11.4% in Q4 2025, indicating significantly improved capital efficiency.

• ROE reached 12.6% in Q4 2025, up from negative territory in Q2 2025, before declining to 8.5% in Q1 2026.

⚠ Margin volatility evident with operating margin swinging from 26.5% in Q4 2025 to 16.3% in Q1 2026.

⚠ ROIC declined from peak 11.4% in Q4 2025 to 6.7% in Q1 2026, signaling potential normalization.

Get alerted when VCYT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VERACYTE, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VCYT

BlackRock, Inc.
$424.3M13,172,618 sh
FMR LLC
$250.1M7,763,849 sh
Artisan Partners Limited Partnership
$177.0M5,496,370 sh
STATE STREET CORP
$162.5M5,043,590 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$143.2M4,444,730 sh
VANGUARD CAPITAL MANAGEMENT LLC
$113.8M3,532,232 sh
ARK Investment Management LLC
$98.4M3,053,818 sh
DIMENSIONAL FUND ADVISORS LP
$92.8M2,881,090 sh
WELLINGTON MANAGEMENT GROUP LLP
$82.4M2,558,285 sh
FIRST TRUST ADVISORS LP
$68.2M2,117,046 sh

Fund	Value	Shares
BlackRock, Inc.	$424.3M	13,172,618
FMR LLC	$250.1M	7,763,849
Artisan Partners Limited Partnership	$177.0M	5,496,370
STATE STREET CORP	$162.5M	5,043,590
VANGUARD PORTFOLIO MANAGEMENT LLC	$143.2M	4,444,730
VANGUARD CAPITAL MANAGEMENT LLC	$113.8M	3,532,232
ARK Investment Management LLC	$98.4M	3,053,818
DIMENSIONAL FUND ADVISORS LP	$92.8M	2,881,090
WELLINGTON MANAGEMENT GROUP LLP	$82.4M	2,558,285
FIRST TRUST ADVISORS LP	$68.2M	2,117,046

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VCYT on your watchlist

Track score changes the day VERACYTE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VCYT a good stock to buy?

13F Pro's AI-powered analysis of VERACYTE, INC. (VCYT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VCYT are available on the VCYT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VCYT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VCYT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VERACYTE, INC.'s investment landscape.